Dog allergy vaccine shows promise in small swedish trial

NCT ID NCT07651891

Disease control Sponsor: Karolinska Institutet Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 30, 2026 · Updated 3 times

Summary

This study tests a dog allergy immunotherapy called Alutard SQ Dog in 40 adults with moderate-to-severe dog allergy. Participants receive increasing doses over 13 weeks, then maintenance shots every 6-8 weeks for a year. Their symptoms and lung function are measured before and after exposure to dogs, both at the start and end of treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: Alutard SQ Dog (allergen immunotherapy)
What this could lead to: If it works, this could provide a long-term way to reduce allergic reactions to dogs, improving quality of life for dog allergy sufferers.
What could go wrong: This is a small, single-center study with only 40 participants and no placebo group, so results may not be widely applicable. Allergen immunotherapy can cause local or systemic allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 50 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria The subject has provided written informed consent to participate in the study. * Age 18-50 years. * Moderate-to-severe allergic symptoms upon exposure to dogs. * Dog allergy confirmed by positive specific IgE. * Considered suitable by the investigator for treatment with Alutard SQ Dog in accordance with the approved Summary of Product Characteristics (SmPC). * Female subjects of childbearing potential must use adequate contraception. * A negative pregnancy test must be obtained prior to enrolment. Exclusion Criteria * Pregnancy or breastfeeding. * Autoimmune or connective tissue disease. * Cardiovascular disease. * Hepatic disease. * Renal disease. * Malignancy. * Upper airway disease (e.g., non-allergic sinusitis or nasal polyposis). * Chronic obstructive or restrictive lung disease. * Treatment with medications that may interfere with the immune response. * Previous immunotherapy or chemotherapy. * Significant chronic disease. * Major metabolic disease. * Alcohol or substance abuse. * Mental or cognitive incapacity that may impair compliance with study procedures. * Known or suspected hypersensitivity to the study product. * Suspected or confirmed bacterial infection. * Clinically relevant allergy to house dust mite. * Current dog ownership. * Any condition that, in the investigator's opinion, may make participation, follow-up, or study assessments inappropriate. * Any subject considered unsuitable for enrolment according to the principles of the Declaration of Helsinki.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Allergic rhinitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

allergic rhinitis asthma atopy, dog disease Rhinitis, Allergic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Allergic rhinitis Asthma (diagnosis)

How to take part

Only the study team decides who joins. These are the ways to reach them.

The places running it

2 sites. The list below names each one and where it is.
The official record

ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

Open the record ↗
A doctor treating you

A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Dog allergy vaccine shows promise in small swedish trial

What the study statuses mean